Canada: CETA Trade Negotiations 2011 – Drug Market Exclusivity In The EU And Canada

Last Updated: October 25 2011

Article by Patrick E. Kierans , Kristin Wall and Jill Daley

A consideration of why Canada should answer the European Union's call for heightened IP protection for pharmaceuticals

This briefing contributes to the current debate around IP rights for pharmaceuticals in Canada.

Against the backdrop of the CETA trade negotiations, Norton Rose Group's Toronto-based head of pharmaceuticals and life sciences, Patrick E. Kierans, and colleagues Kristin Wall and Jill Daley employ a comparative study to highlight why Canada should answer the European Union's call for heightened IP protection for pharmaceuticals.

On average, the EU is approving new drugs faster and enabling patent term restoration, leaving Canadian innovators doubly disadvantaged compared with their second-largest trading partner. Implementing patent term restoration and extending the term of data protection will help to level the playing field with Europe. For the majority of the sampled products, extending data protection by two years appears to provide greater security for innovators without extending overall IP exclusivity for innovative medicines. Increasing the rate of drug approval in Canada will diminish any market exclusivity impact of data protection and patent term restoration, while giving Canadians earlier access to new medicines.

See also our July 2011 briefing: "European Union – Canada debate IP rights for pharmaceuticals" (assessing proposed legal reforms).


Canada and the European Union met in Ottawa this October for what may be the last full round of trade negotiations on the Comprehensive Economic and Trade Agreement (CETA). The issue of harmonizing European and Canadian intellectual property rights for pharmaceuticals remains open for negotiation.

Having already identified pharmaceutical IP rights as an area where Canada must improve, the EU has proposed three legal or regulatory reforms:

  • provide innovator companies with fair treatment under the Patented Medicines (Notice of Compliance) Regulations, namely providing innovators with the same effective right of appeal in court proceedings under these regulations that generic manufacturers have;
  • extend the term of data protection; and
  • implement patent term restoration (PTR).

This briefing focuses on the latter two reforms (data protection and PTR) as both reforms have the potential to affect drug market exclusivity in Canada. While important to innovators for greater market certainty, the proposed reform on effective innovator appeal rights is not specifically addressed as it does not directly impact overall drug market exclusivity, but rather acts as safeguard against a premature finding of patent invalidity or non-infringement.

Data protection and patent term restoration – Canada vs. EU

Data protection in Canada presently provides eligible innovative drugs with eight years of drug market exclusivity, with the possibility of a six-month extension for submitting pediatric trial data. Generic manufacturers are prohibited from filing a comparative drug submission relying, directly or indirectly, on the innovative drug's clinical trial data during the first six years of the eight-year term. No generic will be granted marketing approval until the applicable data protection term has expired.

Data protection in Europe operates similarly, except the total market exclusivity provided is typically 20 percent longer (i.e., 10 years in total with an eight-year no-filing period). An eleventh year of data protection can also be granted for approval of a new use, dosage form, etc.

PTR provides drug market exclusivity by accounting for some of the lost patent term benefit during a drug's development and regulatory approval phase. It is not unusual for a new drug to enter the Canadian market with less than half of its 20-year patent term remaining. PTR is available in Europe in the form of "supplementary protection certificates" (SPC). SPCs cannot restore more than five years to the patent and cannot extend a drug's remaining patent term beyond 14 years. Canada is one of the only developed countries that does not provide for any form of PTR.

A comparative look at drug market exclusivity in the EU (i.e., data protection, patent term, SPC) and Canada (i.e., data protection, patent term) supports the case for heightened data protection and PTR in Canada.


In order to consider the impact of adopting the proposed IP reforms on data protection and PTR in Canada, the authors compared the total market exclusivity provided by data protection and patents for a sample of 22 drugs approved in both Canada and the EU.1 Specifically, the 22 candidate drugs were selected from Canada's Register of Innovative Drugs (Innovative Register), which listed (as of July 2011) 105 "innovative" human drugs granted data protection in Canada.

Twenty-two drugs were selected in order to obtain a 20 percent representative sample of the 105 drugs listed on the Innovative Register. Candidate drugs with the most recent approval dates were selected, and include products with significant IMS global sales.2

In order to assess the comparative drug market exclusivity provided by data protection and patents in Canada and Europe, candidate drugs were required to have: (1) data protection; (2) patents listed on the Canadian Patent Register; and (3) a central European market authorization.

The following data was collected for each candidate drug in both Canada and the EU:

  • date of market approval;3
  • data protection expiry date;4
  • earliest patent expiry date;
  • latest patent expiry date; 5 and
  • where applicable, the grant of an SPC.6


Slower Canadian drug approval times as compared with the EU make a strong case for implementing patent term restoration in Canada.

In 17 of the 22 candidate drugs considered (77%), drugs were approved earlier in the EU than in Canada: time differences ranged from five years (as with Abilify) to four months (as with Ilaris, Daxas). Of the sample drugs considered, Canadian drugs were approved an average of 451.4 days later than in the EU.

Since the date a new drug submission (NDS) is filed in Canada is generally not available in the public domain, we were not able to compare the relative speed of approval for the sample drugs selected. However, according to Health Canada's data on drug submission approval times, the median NDS approval time for 2010, including priority approvals, was 433 days – 1,563 days being the longest approval time and 216 days the shortest approval.7 Comparatively, the European Medicines Agency (EMA) annual report for 2010 states that the total average approval time for central European approvals granted in 2010 was 281 days.8 As a result, EU drugs were, on average, approved 152 days faster than the median Canadian approval.

Slower drug approval denies Canadians timely access to new medicines. Slower drug approval also reduces the patent term: drugs launched in Canada may have far less of the 20-year patent term remaining than drugs launched in the EU.

Canada already clearly stands out amongst virtually all OECD (Organisation for Economic Co-operation and Development) countries for failing to provide PTR. This briefing highlights the impact of this omission in the Canadian IP regime. EU drugs benefit from longer patent terms due to faster drug approval; as well as this, patent terms for EU drugs can be extended (for up to five years) to compensate for any portion of patent term lost for time spent in regulatory drug approval.

Implementing PTR in Canada would compensate in part for the patent term benefit lost due to Canada's slower rate of drug approval. Additionally, to the extent that Canada's approval times materially improve, the likelihood of any PTR being granted would decrease significantly.

Harmonization with the EU (i.e., extending data protection from eight years to 10 years in Canada) would not extend the total market exclusivity granted to Canadian drugs in the majority of cases.

Of the 22 drugs sampled, only eight Canadian drugs had total market exclusivity terms that would be extended were Canada to adopt the EU's data protection regime. This is because most of the candidate drugs considered had patent protection that extended beyond the term of data protection, meaning that the extension of data protection from eight years to 10 years in Canada would have no impact in the majority of cases.

In order to further verify this result, the authors considered all 105 of the human health drugs listed on Health Canada's Innovative Register. Of these drugs, 81 had patents listed on the Canadian Patent Register; 58 of 81 (72%) benefited from patent terms that extended beyond the data protection term. On average, the patent term for these 58 drugs extended 4.5 years past the data protection term.

With respect to the potential impact of PTR, only five of the 22 sampled products had been granted SPCs to date in Europe, which resulted in an average of two to three years of market time compensation for these five products.9

As a result, for drugs with data and patent protection in Canada, it may be concluded that total market exclusivity is governed primarily by the patent term, and not by the term of data protection. Here again, if Canadian drugs were approved faster, earlier approval dates would further diminish the impact of greater data protection market exclusivity over and above patent protection or any PTR.


A comparative look at 22 drugs approved in both the EU and Canada reveals that adopting the proposed CETA IP reforms will not automatically result in longer terms of drug market exclusivity. In many cases, the overall term of drug market exclusivity is governed by the 20-year patent term, which is the same in both Canada and the EU.

Canadian innovators are losing patent term benefit at the front end due to the length of time taken to comply with regulatory requirements. The EU is approving new drugs earlier and facilitating PTR, leaving Canadian innovators doubly disadvantaged, which has a significant impact on global marketing and R&D investment decisions. Implementing PTR is a necessary step to bring Canada up to the same level of patent protection as virtually all of its major trading partners. Extending the data protection term in Canada will provide innovators with more certainty, without extending market exclusivity beyond that already fixed by the patent term in the majority of the drugs considered. Substantially improving the rate of new drug approval in Canada will also diminish the market exclusivity impact of data protection over and above patent protection, at the same time granting Canadians earlier access to new medicines.

* This briefing does not constitute legal advice. The data collected on market exclusivity was done for the sole purpose of this briefing. The authors do not represent or warrant the applicability or expiry of any term of data protection, patent term or patent restoration term for the drugs considered.*


1 Sample drugs considered: Champix, Abilify, Cymbalta, Gardasil, Yondelis, Actemra/Ro-Actemra, Brilinta/Brilique, Ilaris, Prolia, Victoza, Votrient, Daxas, Kuvan, Jevtana, Byetta, Uloric/Adenuric, Gilenya, Cimzia, Banzel/Inovelon, Rapaflo/Silodyx/Urorex, Orencia, and Sprycel.

2 IMS, top-line market data, global and USA sales, accessed at: (last accessed July 2011).

3 Canadian source: Health Canada, Register of Innovative Drugs, accessed at: ; EU source: European Medicines Agency, Database of Human Medicines, accessed at:

4 Canadian source: Health Canada, Register of Innovative Drugs (as above); EU source: Unlike Canada, the EU does not maintain a public register of drugs eligible for data protection. The data protection expiry date was calculated by applying the relevant legislation. See Directive 2004/27/EC of March 31, 2004, and EMA procedural advice for users of the centralised procedure for generic/hybrid applications (January 2011). Based on the latter, the data protection expiry date in the EU was calculated as follows: (1) It was presumed that drugs granted data protection in Canada would also have been granted data protection in the EU; (2) 10 years were added to the date of the central marketing authorization to determine the data protection expiry date; (3) Based on drug approval information available on the EMA website, only one drug (Prolia/Xgeva) possessed a second approval that may have qualified for an 11th year of data protection.

5 Patent listing and expiry dates were obtained from the Canadian Patent Register located at: The equivalent EU patents were located with the Canadian Intellectual Property Office (CIPO) website, the European Patent Office website and QPAT located at:

6 Information on supplementary protection certificates was obtained from the UK Patent Office at

7 Health Canada, Therapeutic Products Directorate Drug Submission Performance Annual Report January – December 2010 (May 16, 2011), page 16 (available from Health Canada on request).

8 European Medicines Agency, Annual Report 2010 (June 28, 2011), page 34, accessed at:

9 Champix, Yondelis, Victoza, Banzel/Inovelon and Orencia.

Norton Rose OR LLP

Norton Rose OR LLP is a member of Norton Rose Group, a leading international legal practice offering a full business law service to many of the world's pre-eminent financial institutions and corporations from offices in Europe, Asia Pacific, Canada, Africa and the Middle East.

The Group's lawyers share industry knowledge and sector expertise across borders to support clients anywhere in the world. The Group is strong in financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and pharmaceuticals and life sciences.

Norton Rose Group has more than 2600 lawyers operating from 39 offices in Abu Dhabi, Amsterdam, Athens, Bahrain, Bangkok, Beijing, Brisbane, Brussels, Calgary, Canberra, Cape Town, Dubai, Durban, Frankfurt, Hamburg, Hong Kong, Johannesburg, London, Melbourne, Milan, Montréal, Moscow, Munich, Ottawa, Paris, Perth, Piraeus, Prague, Québec, Rome, Shanghai, Singapore, Sydney, Tokyo, Toronto and Warsaw; and from associate offices in Dar es Salaam, Ho Chi Minh City and Jakarta.

Norton Rose Group comprises Norton Rose LLP, Norton Rose Australia, Norton Rose OR LLP, Norton Rose South Africa (incorporated as Deneys Reitz Inc), and their respective affiliates.

On January 1, 2012, Macleod Dixon merges with Norton Rose OR, creating a global energy and mining powerhouse within Norton Rose Group. For more information, please visit

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.